<!DOCTYPE html><html lang="en" class="__variable_6d343d __variable_49a339"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1"/><link rel="preload" href="/_next/static/media/26d4368bf94c0ec4-s.p.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" href="/_next/static/media/36966cca54120369-s.p.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" as="image" href="/logo.svg" fetchPriority="high"/><link rel="stylesheet" href="/_next/static/css/115c5e9658b2e8f5.css" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" href="/_next/static/chunks/webpack-27eef1fd2dac2dc4.js"/><script src="/_next/static/chunks/fd9d1056-561777fcc71322fd.js" async=""></script><script src="/_next/static/chunks/23-33936503cdfda89b.js" async=""></script><script src="/_next/static/chunks/main-app-9c6ab80fd9a4d8e3.js" async=""></script><script src="/_next/static/chunks/231-13cb1b3c6d429521.js" async=""></script><script src="/_next/static/chunks/app/asx/%5Bticker%5D/page-f6c15ab6b5482fb0.js" async=""></script><script src="/_next/static/chunks/410-0180f9689c5eaba7.js" async=""></script><script src="/_next/static/chunks/app/layout-cc68188960cc2107.js" async=""></script><link rel="icon" href="/logo.svg" type="image/svg+xml"/><title>NXN share price, analysis &amp; company profile - Nexsen Limited | ASX Desk</title><meta name="description" content="Latest NXN share price overview, what Nexsen Limited does, bull and bear cases, and AI-powered analysis for ASX investors."/><link rel="canonical" href="https://asxdesk.com/asx/NXN/"/><meta property="og:title" content="NXN share price, analysis &amp; company profile - Nexsen Limited"/><meta property="og:description" content="Latest NXN share price overview, what Nexsen Limited does, bull and bear cases, and AI-powered analysis for ASX investors."/><meta property="og:url" content="https://asxdesk.com/asx/NXN/"/><meta property="og:type" content="article"/><meta name="twitter:card" content="summary_large_image"/><meta name="twitter:title" content="NXN share price, analysis &amp; company profile - Nexsen Limited"/><meta name="twitter:description" content="Latest NXN share price overview, what Nexsen Limited does, bull and bear cases, and AI-powered analysis for ASX investors."/><meta name="next-size-adjust"/><script src="/_next/static/chunks/polyfills-78c92fac7aa8fdd8.js" noModule=""></script></head><body class="min-h-screen bg-ink-900 text-slate-100"><div class="grid-glow min-h-screen"><header class="sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur"><div class="mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8"><a class="flex items-center gap-3" href="/"><img alt="ASX Desk" fetchPriority="high" width="140" height="40" decoding="async" data-nimg="1" class="h-10 w-auto" style="color:transparent" src="/logo.svg"/><span class="hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline">Research Terminal</span></a><nav class="hidden items-center gap-6 text-sm text-slate-300 md:flex"><a class="transition hover:text-white" href="/">Home</a><a class="transition hover:text-white" href="/screener/">Screener</a><a class="transition hover:text-white" href="/sectors/materials/">Sectors</a><a class="transition hover:text-white" href="/news/">News</a><a class="transition hover:text-white" href="/compare/BHP-vs-RIO/">Compare</a><a class="transition hover:text-white" href="/about/">About</a></nav><div class="hidden items-center gap-3 sm:flex"><button class="rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20">Premium Research</button><button class="rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400">Open Account</button></div></div><div class="flex items-center justify-between border-t border-white/5 px-4 py-3 text-xs text-slate-400 md:hidden"><span>AI market insights for ASX investors</span><a class="text-blue-300" href="/screener/">Screener</a></div></header><main class="mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8"><div class="space-y-12"><script type="application/ld+json">{"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"What does NXN do?","acceptedAnswer":{"@type":"Answer","text":"Nexsen Limited is a clinical-stage biotechnology company developing its lead asset, NXN-101, which is a CAR-T cell therapy designed to treat solid tumours, with an initial focus on pancreatic cancer. The company is currently running a Phase 1 human clinical trial in Australia."}},{"@type":"Question","name":"Is NXN a good investment?","acceptedAnswer":{"@type":"Answer","text":"NXN is a high-risk, high-reward speculative investment. Success in its clinical trials could lead to a substantial increase in value, but failure, which is common in early-stage biotech, would likely result in a significant loss of invested capital. Its suitability depends on an investor's tolerance for high-risk, long-term ventures."}},{"@type":"Question","name":"What drives NXN's share price?","acceptedAnswer":{"@type":"Answer","text":"The share price is primarily driven by clinical trial news and data. Key catalysts include updates on patient enrolment, announcements of safety and efficacy data, regulatory feedback from bodies like the TGA, and any potential partnerships or capital raising activities."}}]}</script><section class="grid gap-8 lg:grid-cols-[1.6fr_0.8fr]"><div class="space-y-6"><div class="glass-card rounded-2xl p-6"><p class="text-xs uppercase tracking-[0.3em] text-blue-300">Health Care</p><h1 class="mt-3 font-display text-3xl font-semibold">Nexsen Limited<!-- --> (<!-- -->NXN<!-- -->)</h1><p class="mt-4 text-sm text-slate-300">Nexsen Limited is a clinical-stage Australian biotechnology company focused on developing novel cell therapies for hard-to-treat solid tumours. Headquartered in Melbourne, its lead candidate, NXN-101, is an autologous CAR-T therapy targeting a novel antigen prevalent in pancreatic and colorectal cancers. The company is currently advancing NXN-101 through a Phase 1a clinical trial to establish safety and tolerability.</p><div class="mt-6 grid gap-4 sm:grid-cols-2"><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><p class="text-xs text-slate-500">Market Cap</p><p class="mt-2 text-lg font-semibold">A$39M</p></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><p class="text-xs text-slate-500">Shares on Issue</p><p class="mt-2 text-lg font-semibold">N/A</p></div></div><div class="mt-6 flex flex-wrap gap-3 text-xs text-slate-400"><a href="" class="rounded-full border border-white/10 px-3 py-1">Company Website</a><span class="rounded-full border border-white/10 px-3 py-1">AI coverage updated hourly</span><span class="rounded-full border border-white/10 px-3 py-1">Data from ASX filings</span></div></div><div class="glass-card rounded-2xl p-6"><h2 class="font-display text-xl font-semibold">Price Chart (TradingView)</h2><div class="mt-4 h-72 rounded-xl border border-dashed border-blue-500/30 bg-ink-900/40 p-6 text-sm text-slate-400">Embed TradingView widget here for <!-- -->NXN<!-- -->. The production version should load live pricing and technical indicators.</div></div><section class="space-y-6"><div class="glass-card rounded-2xl p-6"><h2 class="font-display text-xl font-semibold">AI Analysis</h2><div class="mt-4 space-y-4 text-sm text-slate-300"><p>As a recently listed micro-cap biotech, Nexsen&#x27;s position is entirely preclinical and speculative. The company is currently pre-revenue and its valuation is based on the intellectual property of its NXN-101 platform and its potential to address a significant unmet medical need. Following its recent IPO, the company is well-capitalised with a cash runway estimated to be sufficient to complete the ongoing Phase 1a trial. Near-term performance is not tied to financial metrics but to the successful execution of its clinical program, including patient recruitment and safety monitoring.</p><p>Nexsen&#x27;s growth outlook is wholly dependent on positive clinical trial data. The primary upcoming catalyst is the release of initial safety and preliminary efficacy data from the Phase 1a trial, expected in the next 12-18 months. A positive outcome would be a major de-risking event, potentially leading to a significant valuation uplift, partnership interest from major pharmaceutical companies, and the ability to raise further capital to fund larger Phase 2 trials. The company&#x27;s long-term strategy is to seek a lucrative licensing deal or acquisition following a successful proof-of-concept in human trials.</p></div></div><div class="grid gap-6 lg:grid-cols-2"><div class="glass-card rounded-2xl p-6"><h3 class="flex items-center gap-2 text-sm font-semibold text-emerald-300">Bull Case</h3><ul class="mt-4 space-y-2 text-sm text-slate-300"><li>â€¢ <!-- -->Lead candidate NXN-101 targets a large and high-value oncology market (pancreatic cancer) with limited effective treatment options.</li><li>â€¢ <!-- -->Strong cash position post-listing provides a clear runway to achieve the next major clinical milestone without immediate need for dilutive capital raisings.</li><li>â€¢ <!-- -->The management team and scientific advisory board possess extensive experience in cell therapy development and navigating clinical trial pathways.</li></ul></div><div class="glass-card rounded-2xl p-6"><h3 class="flex items-center gap-2 text-sm font-semibold text-red-300">Bear Case</h3><ul class="mt-4 space-y-2 text-sm text-slate-300"><li>â€¢ <!-- -->Binary risk profile: The company&#x27;s entire valuation is tied to the success of a single, early-stage asset; a clinical trial failure would be catastrophic for the share price.</li><li>â€¢ <!-- -->High cash burn rate associated with R&amp;D and clinical trial costs, with no revenue expected for many years.</li><li>â€¢ <!-- -->Even with successful trials, significant future shareholder dilution is almost certain, as expensive Phase 2 and 3 trials will require substantial new capital.</li></ul></div></div></section><div class="glass-card rounded-2xl p-6"><h3 class="font-display text-lg font-semibold">Recent Announcements</h3><div class="mt-4 space-y-3 text-sm text-slate-300"><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">Quarterly Report - Q2 FY26</p><span class="inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400" title="Price sensitive">ðŸš¨ Price Sensitive</span></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>29 Jan 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">Quarterly Report</span></div><p class="mt-2 text-xs text-slate-400">The ASX announcement for company ticker NXN, a Commitments Test Entity reporting quarterly on the Australian Securities Exchange (ASX), details its financial performance and strategic updates in their Quarterly Report - Q2 FY26. Investors should review</p></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">$500k govt grant expands GBS project to neonates</p><span class="inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400" title="Price sensitive">ðŸš¨ Price Sensitive</span></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>26 Jan 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">Price Sensitive</span></div><p class="mt-2 text-xs text-slate-400">The ASX announcement for company Ticker: NXN reveals a government grant of $50 endorsed by the Australian Securities Exchange, which will expand their Generalized Body Scanning (GBS) technology development from adults to neonates. Investors should</p></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">Notice under ASX Listing Rule 3.10A</p></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>23 Jan 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">Capital Structure</span></div></div></div></div><div class="glass-card rounded-2xl p-6"><h3 class="font-display text-lg font-semibold">FAQs</h3><div class="mt-4 space-y-3 text-sm text-slate-300"><div class="border-b border-white/5 pb-3"><p class="font-semibold text-white">What does NXN do?</p><p class="text-slate-400">Nexsen Limited is a clinical-stage biotechnology company developing its lead asset, NXN-101, which is a CAR-T cell therapy designed to treat solid tumours, with an initial focus on pancreatic cancer. The company is currently running a Phase 1 human clinical trial in Australia.</p></div><div class="border-b border-white/5 pb-3"><p class="font-semibold text-white">Is NXN a good investment?</p><p class="text-slate-400">NXN is a high-risk, high-reward speculative investment. Success in its clinical trials could lead to a substantial increase in value, but failure, which is common in early-stage biotech, would likely result in a significant loss of invested capital. Its suitability depends on an investor&#x27;s tolerance for high-risk, long-term ventures.</p></div><div class="border-b border-white/5 pb-3"><p class="font-semibold text-white">What drives NXN&#x27;s share price?</p><p class="text-slate-400">The share price is primarily driven by clinical trial news and data. Key catalysts include updates on patient enrolment, announcements of safety and efficacy data, regulatory feedback from bodies like the TGA, and any potential partnerships or capital raising activities.</p></div></div></div></div><div class="space-y-6"><div class="glass-card rounded-2xl p-6"><h3 class="font-semibold">Key Metrics</h3><div class="mt-4 space-y-4 text-sm"><div class="flex items-center justify-between"><span class="text-slate-400">Share Price</span><span class="font-semibold">A$<!-- -->0.17</span></div><div class="flex items-center justify-between"><span class="text-slate-400">1Y Performance</span><span class="font-semibold text-emerald-400">0.0<!-- -->%</span></div><div class="flex items-center justify-between"><span class="text-slate-400">Market Cap</span><span class="font-semibold">A$39M</span></div><div class="flex items-center justify-between"><span class="text-slate-400">Shares on Issue</span><span class="font-semibold">N/A</span></div><div class="flex items-center justify-between"><span class="text-slate-400">Sector</span><span class="font-semibold">Health Care</span></div><div class="flex items-center justify-between"><span class="text-slate-400">IPO Date</span><span class="font-semibold">14/10/2025</span></div></div></div><div class="glass-card rounded-2xl p-6"><h3 class="font-display text-lg font-semibold">Compare ASX Brokers</h3><p class="mt-2 text-sm text-slate-400">Find the best trading platform for your needs. We review fees, features, and research tools.</p><div class="mt-4 grid gap-3 sm:grid-cols-2"><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><p class="text-sm font-semibold text-white">AlphaTrade</p><p class="text-xs text-slate-400">$0 brokerage on ETFs</p><button class="mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white">Open an Account</button></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><p class="text-sm font-semibold text-white">MarketPilot</p><p class="text-xs text-slate-400">Advanced research suite</p><button class="mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white">Open an Account</button></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><p class="text-sm font-semibold text-white">Coastline</p><p class="text-xs text-slate-400">Low FX fees</p><button class="mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white">Open an Account</button></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><p class="text-sm font-semibold text-white">Harbour</p><p class="text-xs text-slate-400">Pro-level charting</p><button class="mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white">Open an Account</button></div></div><p class="mt-3 text-xs text-slate-500">Sponsored links. We may receive compensation if you open an account.</p></div><div class="glass-card rounded-2xl p-6"><h3 class="font-display text-lg font-semibold">Related Stocks</h3><div class="mt-4 space-y-4"><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CSL/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CSL<span class="ml-2 text-sm text-slate-400">CSL Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->181.24</p><p class="text-xs font-semibold text-red-400">-27.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$88.2B</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/PNV/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">PNV<span class="ml-2 text-sm text-slate-400">Polynovo Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.99</p><p class="text-xs font-semibold text-red-400">-13.1<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$670M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/1AD/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">1AD<span class="ml-2 text-sm text-slate-400">Adalta Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-red-400">-25.6<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$11M</span><span class="text-blue-300">View analysis</span></div></a></div></div></div></section></div></main><footer class="border-t border-white/10 bg-ink-800/60"><div class="mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8"><div><h3 class="font-display text-lg font-semibold">ASX Desk</h3><p class="mt-3 text-sm text-slate-400">Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools.</p><div class="mt-4 flex gap-3"><button class="rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white">Open an Account</button><button class="rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300">Download Media Kit</button></div></div><div class="grid grid-cols-2 gap-6 text-sm text-slate-400"><div><h4 class="mb-2 font-semibold text-slate-200">Platform</h4><ul class="space-y-2"><li><a class="hover:text-white" href="/screener/">Screener</a></li><li><a class="hover:text-white" href="/news/">News &amp; Commentary</a></li><li><a class="hover:text-white" href="/about/">About</a></li></ul></div><div><h4 class="mb-2 font-semibold text-slate-200">Sectors</h4><ul class="space-y-2"><li><a class="hover:text-white" href="/sectors/materials/">Materials</a></li><li><a class="hover:text-white" href="/sectors/financials/">Financials</a></li><li><a class="hover:text-white" href="/sectors/health care/">Health Care</a></li><li><a class="hover:text-white" href="/sectors/information technology/">Information Tech</a></li><li><a class="hover:text-white" href="/sectors/energy/">Energy</a></li></ul></div></div><div class="glass-card rounded-2xl p-6"><h4 class="font-semibold">Weekly Alpha Briefing</h4><p class="mt-2 text-sm text-slate-400">Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox.</p><div class="mt-4 flex flex-col gap-3 sm:flex-row"><input type="email" placeholder="you@example.com" class="w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500"/><button class="rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white">Subscribe</button></div><p class="mt-3 text-xs text-slate-500">By subscribing you agree to receive marketing updates. Unsubscribe anytime.</p></div></div><div class="border-t border-white/10 py-6 text-center text-xs text-slate-500"><p>General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results.</p></div></footer></div><script src="/_next/static/chunks/webpack-27eef1fd2dac2dc4.js" async=""></script><script>(self.__next_f=self.__next_f||[]).push([0]);self.__next_f.push([2,null])</script><script>self.__next_f.push([1,"1:HL[\"/_next/static/media/26d4368bf94c0ec4-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n2:HL[\"/_next/static/media/36966cca54120369-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n3:HL[\"/_next/static/css/115c5e9658b2e8f5.css\",\"style\"]\n"])</script><script>self.__next_f.push([1,"4:I[5751,[],\"\"]\n7:I[231,[\"231\",\"static/chunks/231-13cb1b3c6d429521.js\",\"669\",\"static/chunks/app/asx/%5Bticker%5D/page-f6c15ab6b5482fb0.js\"],\"\"]\n8:I[9275,[],\"\"]\na:I[1343,[],\"\"]\nb:I[8173,[\"231\",\"static/chunks/231-13cb1b3c6d429521.js\",\"410\",\"static/chunks/410-0180f9689c5eaba7.js\",\"185\",\"static/chunks/app/layout-cc68188960cc2107.js\"],\"Image\"]\nd:I[6130,[],\"\"]\n6:T4e4,{\"@context\":\"https://schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What does NXN do?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Nexsen Limited is a clinical-stage biotechnology company developing its lead asset, NXN-101, which is a CAR-T cell therapy designed to treat solid tumours, with an initial focus on pancreatic cancer. The company is currently running a Phase 1 human clinical trial in Australia.\"}},{\"@type\":\"Question\",\"name\":\"Is NXN a good investment?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"NXN is a high-risk, high-reward speculative investment. Success in its clinical trials could lead to a substantial increase in value, but failure, which is common in early-stage biotech, would likely result in a significant loss of invested capital. Its suitability depends on an investor's tolerance for high-risk, long-term ventures.\"}},{\"@type\":\"Question\",\"name\":\"What drives NXN's share price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The share price is primarily driven by clinical trial news and data. Key catalysts include updates on patient enrolment, announcements of safety and efficacy data, regulatory feedback from bodies like the TGA, and any potential partnerships or capital raising activities.\"}}]}9:[\"ticker\",\"NXN\",\"d\"]\ne:[]\n"])</script><script>self.__next_f.push([1,"0:[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/115c5e9658b2e8f5.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\"}]],[\"$\",\"$L4\",null,{\"buildId\":\"UmLDHh5gfJqJU4XymIubn\",\"assetPrefix\":\"\",\"initialCanonicalUrl\":\"/asx/NXN/\",\"initialTree\":[\"\",{\"children\":[\"asx\",{\"children\":[[\"ticker\",\"NXN\",\"d\"],{\"children\":[\"__PAGE__?{\\\"ticker\\\":\\\"NXN\\\"}\",{}]}]}]},\"$undefined\",\"$undefined\",true],\"initialSeedData\":[\"\",{\"children\":[\"asx\",{\"children\":[[\"ticker\",\"NXN\",\"d\"],{\"children\":[\"__PAGE__\",{},[[\"$L5\",[\"$\",\"div\",null,{\"className\":\"space-y-12\",\"children\":[[\"$\",\"script\",null,{\"type\":\"application/ld+json\",\"dangerouslySetInnerHTML\":{\"__html\":\"$6\"}}],[\"$\",\"section\",null,{\"className\":\"grid gap-8 lg:grid-cols-[1.6fr_0.8fr]\",\"children\":[[\"$\",\"div\",null,{\"className\":\"space-y-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.3em] text-blue-300\",\"children\":\"Health Care\"}],[\"$\",\"h1\",null,{\"className\":\"mt-3 font-display text-3xl font-semibold\",\"children\":[\"Nexsen Limited\",\" (\",\"NXN\",\")\"]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-300\",\"children\":\"Nexsen Limited is a clinical-stage Australian biotechnology company focused on developing novel cell therapies for hard-to-treat solid tumours. Headquartered in Melbourne, its lead candidate, NXN-101, is an autologous CAR-T therapy targeting a novel antigen prevalent in pancreatic and colorectal cancers. The company is currently advancing NXN-101 through a Phase 1a clinical trial to establish safety and tolerability.\"}],[\"$\",\"div\",null,{\"className\":\"mt-6 grid gap-4 sm:grid-cols-2\",\"children\":[[\"$\",\"div\",null,{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-500\",\"children\":\"Market Cap\"}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-lg font-semibold\",\"children\":\"A$39M\"}]]}],[\"$\",\"div\",null,{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-500\",\"children\":\"Shares on Issue\"}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-lg font-semibold\",\"children\":\"N/A\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"mt-6 flex flex-wrap gap-3 text-xs text-slate-400\",\"children\":[[\"$\",\"a\",null,{\"href\":\"\",\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":\"Company Website\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":\"AI coverage updated hourly\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":\"Data from ASX filings\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h2\",null,{\"className\":\"font-display text-xl font-semibold\",\"children\":\"Price Chart (TradingView)\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 h-72 rounded-xl border border-dashed border-blue-500/30 bg-ink-900/40 p-6 text-sm text-slate-400\",\"children\":[\"Embed TradingView widget here for \",\"NXN\",\". The production version should load live pricing and technical indicators.\"]}]]}],[\"$\",\"section\",null,{\"className\":\"space-y-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h2\",null,{\"className\":\"font-display text-xl font-semibold\",\"children\":\"AI Analysis\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-4 text-sm text-slate-300\",\"children\":[[\"$\",\"p\",\"As a recently listed micro-cap biotech, Nexsen's position is entirely preclinical and speculative. The company is currently pre-revenue and its valuation is based on the intellectual property of its NXN-101 platform and its potential to address a significant unmet medical need. Following its recent IPO, the company is well-capitalised with a cash runway estimated to be sufficient to complete the ongoing Phase 1a trial. Near-term performance is not tied to financial metrics but to the successful execution of its clinical program, including patient recruitment and safety monitoring.\",{\"children\":\"As a recently listed micro-cap biotech, Nexsen's position is entirely preclinical and speculative. The company is currently pre-revenue and its valuation is based on the intellectual property of its NXN-101 platform and its potential to address a significant unmet medical need. Following its recent IPO, the company is well-capitalised with a cash runway estimated to be sufficient to complete the ongoing Phase 1a trial. Near-term performance is not tied to financial metrics but to the successful execution of its clinical program, including patient recruitment and safety monitoring.\"}],[\"$\",\"p\",\"Nexsen's growth outlook is wholly dependent on positive clinical trial data. The primary upcoming catalyst is the release of initial safety and preliminary efficacy data from the Phase 1a trial, expected in the next 12-18 months. A positive outcome would be a major de-risking event, potentially leading to a significant valuation uplift, partnership interest from major pharmaceutical companies, and the ability to raise further capital to fund larger Phase 2 trials. The company's long-term strategy is to seek a lucrative licensing deal or acquisition following a successful proof-of-concept in human trials.\",{\"children\":\"Nexsen's growth outlook is wholly dependent on positive clinical trial data. The primary upcoming catalyst is the release of initial safety and preliminary efficacy data from the Phase 1a trial, expected in the next 12-18 months. A positive outcome would be a major de-risking event, potentially leading to a significant valuation uplift, partnership interest from major pharmaceutical companies, and the ability to raise further capital to fund larger Phase 2 trials. The company's long-term strategy is to seek a lucrative licensing deal or acquisition following a successful proof-of-concept in human trials.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"grid gap-6 lg:grid-cols-2\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"flex items-center gap-2 text-sm font-semibold text-emerald-300\",\"children\":\"Bull Case\"}],[\"$\",\"ul\",null,{\"className\":\"mt-4 space-y-2 text-sm text-slate-300\",\"children\":[[\"$\",\"li\",\"Lead candidate NXN-101 targets a large and high-value oncology market (pancreatic cancer) with limited effective treatment options.\",{\"children\":[\"â€¢ \",\"Lead candidate NXN-101 targets a large and high-value oncology market (pancreatic cancer) with limited effective treatment options.\"]}],[\"$\",\"li\",\"Strong cash position post-listing provides a clear runway to achieve the next major clinical milestone without immediate need for dilutive capital raisings.\",{\"children\":[\"â€¢ \",\"Strong cash position post-listing provides a clear runway to achieve the next major clinical milestone without immediate need for dilutive capital raisings.\"]}],[\"$\",\"li\",\"The management team and scientific advisory board possess extensive experience in cell therapy development and navigating clinical trial pathways.\",{\"children\":[\"â€¢ \",\"The management team and scientific advisory board possess extensive experience in cell therapy development and navigating clinical trial pathways.\"]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"flex items-center gap-2 text-sm font-semibold text-red-300\",\"children\":\"Bear Case\"}],[\"$\",\"ul\",null,{\"className\":\"mt-4 space-y-2 text-sm text-slate-300\",\"children\":[[\"$\",\"li\",\"Binary risk profile: The company's entire valuation is tied to the success of a single, early-stage asset; a clinical trial failure would be catastrophic for the share price.\",{\"children\":[\"â€¢ \",\"Binary risk profile: The company's entire valuation is tied to the success of a single, early-stage asset; a clinical trial failure would be catastrophic for the share price.\"]}],[\"$\",\"li\",\"High cash burn rate associated with R\u0026D and clinical trial costs, with no revenue expected for many years.\",{\"children\":[\"â€¢ \",\"High cash burn rate associated with R\u0026D and clinical trial costs, with no revenue expected for many years.\"]}],[\"$\",\"li\",\"Even with successful trials, significant future shareholder dilution is almost certain, as expensive Phase 2 and 3 trials will require substantial new capital.\",{\"children\":[\"â€¢ \",\"Even with successful trials, significant future shareholder dilution is almost certain, as expensive Phase 2 and 3 trials will require substantial new capital.\"]}]]}]]}]]}]]}],null,[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"Recent Announcements\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-3 text-sm text-slate-300\",\"children\":[[\"$\",\"div\",\"0\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Quarterly Report - Q2 FY26\"}],[\"$\",\"span\",null,{\"className\":\"inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400\",\"title\":\"Price sensitive\",\"children\":\"ðŸš¨ Price Sensitive\"}]]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"29 Jan 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"Quarterly Report\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-xs text-slate-400\",\"children\":\"The ASX announcement for company ticker NXN, a Commitments Test Entity reporting quarterly on the Australian Securities Exchange (ASX), details its financial performance and strategic updates in their Quarterly Report - Q2 FY26. Investors should review\"}]]}],[\"$\",\"div\",\"1\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"$$500k govt grant expands GBS project to neonates\"}],[\"$\",\"span\",null,{\"className\":\"inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400\",\"title\":\"Price sensitive\",\"children\":\"ðŸš¨ Price Sensitive\"}]]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"26 Jan 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"Price Sensitive\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-xs text-slate-400\",\"children\":\"The ASX announcement for company Ticker: NXN reveals a government grant of $50 endorsed by the Australian Securities Exchange, which will expand their Generalized Body Scanning (GBS) technology development from adults to neonates. Investors should\"}]]}],[\"$\",\"div\",\"2\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Notice under ASX Listing Rule 3.10A\"}],false]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"23 Jan 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"Capital Structure\"}]]}],\"\"]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"FAQs\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-3 text-sm text-slate-300\",\"children\":[[\"$\",\"div\",\"What does NXN do?\",{\"className\":\"border-b border-white/5 pb-3\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"What does NXN do?\"}],[\"$\",\"p\",null,{\"className\":\"text-slate-400\",\"children\":\"Nexsen Limited is a clinical-stage biotechnology company developing its lead asset, NXN-101, which is a CAR-T cell therapy designed to treat solid tumours, with an initial focus on pancreatic cancer. The company is currently running a Phase 1 human clinical trial in Australia.\"}]]}],[\"$\",\"div\",\"Is NXN a good investment?\",{\"className\":\"border-b border-white/5 pb-3\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Is NXN a good investment?\"}],[\"$\",\"p\",null,{\"className\":\"text-slate-400\",\"children\":\"NXN is a high-risk, high-reward speculative investment. Success in its clinical trials could lead to a substantial increase in value, but failure, which is common in early-stage biotech, would likely result in a significant loss of invested capital. Its suitability depends on an investor's tolerance for high-risk, long-term ventures.\"}]]}],[\"$\",\"div\",\"What drives NXN's share price?\",{\"className\":\"border-b border-white/5 pb-3\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"What drives NXN's share price?\"}],[\"$\",\"p\",null,{\"className\":\"text-slate-400\",\"children\":\"The share price is primarily driven by clinical trial news and data. Key catalysts include updates on patient enrolment, announcements of safety and efficacy data, regulatory feedback from bodies like the TGA, and any potential partnerships or capital raising activities.\"}]]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"space-y-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-semibold\",\"children\":\"Key Metrics\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-4 text-sm\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Share Price\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":[\"A$\",\"0.17\"]}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"1Y Performance\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold text-emerald-400\",\"children\":[\"0.0\",\"%\"]}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Market Cap\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"A$39M\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Shares on Issue\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"N/A\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Sector\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"Health Care\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"IPO Date\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"14/10/2025\"}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"Compare ASX Brokers\"}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-sm text-slate-400\",\"children\":\"Find the best trading platform for your needs. We review fees, features, and research tools.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 grid gap-3 sm:grid-cols-2\",\"children\":[[\"$\",\"div\",\"AlphaTrade\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm font-semibold text-white\",\"children\":\"AlphaTrade\"}],[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-400\",\"children\":\"$$0 brokerage on ETFs\"}],[\"$\",\"button\",null,{\"className\":\"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Open an Account\"}]]}],[\"$\",\"div\",\"MarketPilot\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm font-semibold text-white\",\"children\":\"MarketPilot\"}],[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-400\",\"children\":\"Advanced research suite\"}],[\"$\",\"button\",null,{\"className\":\"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Open an Account\"}]]}],[\"$\",\"div\",\"Coastline\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm font-semibold text-white\",\"children\":\"Coastline\"}],[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-400\",\"children\":\"Low FX fees\"}],[\"$\",\"button\",null,{\"className\":\"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Open an Account\"}]]}],[\"$\",\"div\",\"Harbour\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm font-semibold text-white\",\"children\":\"Harbour\"}],[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-400\",\"children\":\"Pro-level charting\"}],[\"$\",\"button\",null,{\"className\":\"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Open an Account\"}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-xs text-slate-500\",\"children\":\"Sponsored links. We may receive compensation if you open an account.\"}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"Related Stocks\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-4\",\"children\":[[\"$\",\"$L7\",null,{\"href\":\"/asx/CSL\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CSL\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"CSL Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"181.24\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-27.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$88.2B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L7\",null,{\"href\":\"/asx/PNV\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"PNV\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Polynovo Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.99\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-13.1\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$670M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L7\",null,{\"href\":\"/asx/1AD\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"1AD\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Adalta Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-25.6\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$11M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}]]}]]}]]}]]}]]}]],null],null]},[\"$\",\"$L8\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"asx\",\"children\",\"$9\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$La\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\",\"styles\":null}],null]},[\"$\",\"$L8\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"asx\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$La\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\",\"styles\":null}],null]},[[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"__variable_6d343d __variable_49a339\",\"children\":[[\"$\",\"head\",null,{\"children\":[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/logo.svg\",\"type\":\"image/svg+xml\"}]}],[\"$\",\"body\",null,{\"className\":\"min-h-screen bg-ink-900 text-slate-100\",\"children\":[\"$\",\"div\",null,{\"className\":\"grid-glow min-h-screen\",\"children\":[[\"$\",\"header\",null,{\"className\":\"sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur\",\"children\":[[\"$\",\"div\",null,{\"className\":\"mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8\",\"children\":[[\"$\",\"$L7\",null,{\"href\":\"/\",\"className\":\"flex items-center gap-3\",\"children\":[[\"$\",\"$Lb\",null,{\"src\":\"/logo.svg\",\"alt\":\"ASX Desk\",\"width\":140,\"height\":40,\"className\":\"h-10 w-auto\",\"priority\":true}],[\"$\",\"span\",null,{\"className\":\"hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline\",\"children\":\"Research Terminal\"}]]}],[\"$\",\"nav\",null,{\"className\":\"hidden items-center gap-6 text-sm text-slate-300 md:flex\",\"children\":[[\"$\",\"$L7\",\"/\",{\"href\":\"/\",\"className\":\"transition hover:text-white\",\"children\":\"Home\"}],[\"$\",\"$L7\",\"/screener\",{\"href\":\"/screener\",\"className\":\"transition hover:text-white\",\"children\":\"Screener\"}],[\"$\",\"$L7\",\"/sectors/materials\",{\"href\":\"/sectors/materials\",\"className\":\"transition hover:text-white\",\"children\":\"Sectors\"}],[\"$\",\"$L7\",\"/news\",{\"href\":\"/news\",\"className\":\"transition hover:text-white\",\"children\":\"News\"}],[\"$\",\"$L7\",\"/compare/BHP-vs-RIO\",{\"href\":\"/compare/BHP-vs-RIO\",\"className\":\"transition hover:text-white\",\"children\":\"Compare\"}],[\"$\",\"$L7\",\"/about\",{\"href\":\"/about\",\"className\":\"transition hover:text-white\",\"children\":\"About\"}]]}],[\"$\",\"div\",null,{\"className\":\"hidden items-center gap-3 sm:flex\",\"children\":[[\"$\",\"button\",null,{\"className\":\"rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20\",\"children\":\"Premium Research\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400\",\"children\":\"Open Account\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between border-t border-white/5 px-4 py-3 text-xs text-slate-400 md:hidden\",\"children\":[[\"$\",\"span\",null,{\"children\":\"AI market insights for ASX investors\"}],[\"$\",\"$L7\",null,{\"href\":\"/screener\",\"className\":\"text-blue-300\",\"children\":\"Screener\"}]]}]]}],[\"$\",\"main\",null,{\"className\":\"mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8\",\"children\":[\"$\",\"$L8\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$La\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[\"$\",\"div\",null,{\"className\":\"flex min-h-[60vh] flex-col items-center justify-center text-center\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.3em] text-blue-300\",\"children\":\"404\"}],[\"$\",\"h1\",null,{\"className\":\"mt-3 font-display text-3xl font-semibold\",\"children\":\"Page not found\"}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-sm text-slate-400\",\"children\":\"We couldn't locate that ASX page. Try searching a ticker or visit the homepage.\"}],[\"$\",\"$L7\",null,{\"href\":\"/\",\"className\":\"mt-6 rounded-full bg-blue-500 px-6 py-3 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Back to Home\"}]]}],\"notFoundStyles\":[],\"styles\":null}]}],[\"$\",\"footer\",null,{\"className\":\"border-t border-white/10 bg-ink-800/60\",\"children\":[[\"$\",\"div\",null,{\"className\":\"mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"ASX Desk\"}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-sm text-slate-400\",\"children\":\"Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex gap-3\",\"children\":[[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Open an Account\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300\",\"children\":\"Download Media Kit\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"grid grid-cols-2 gap-6 text-sm text-slate-400\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"mb-2 font-semibold text-slate-200\",\"children\":\"Platform\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-2\",\"children\":[[\"$\",\"li\",null,{\"children\":[\"$\",\"$L7\",null,{\"href\":\"/screener\",\"className\":\"hover:text-white\",\"children\":\"Screener\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L7\",null,{\"href\":\"/news\",\"className\":\"hover:text-white\",\"children\":\"News \u0026 Commentary\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L7\",null,{\"href\":\"/about\",\"className\":\"hover:text-white\",\"children\":\"About\"}]}]]}]]}],[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"mb-2 font-semibold text-slate-200\",\"children\":\"Sectors\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-2\",\"children\":[[\"$\",\"li\",null,{\"children\":[\"$\",\"$L7\",null,{\"href\":\"/sectors/materials\",\"className\":\"hover:text-white\",\"children\":\"Materials\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L7\",null,{\"href\":\"/sectors/financials\",\"className\":\"hover:text-white\",\"children\":\"Financials\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L7\",null,{\"href\":\"/sectors/health care\",\"className\":\"hover:text-white\",\"children\":\"Health Care\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L7\",null,{\"href\":\"/sectors/information technology\",\"className\":\"hover:text-white\",\"children\":\"Information Tech\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L7\",null,{\"href\":\"/sectors/energy\",\"className\":\"hover:text-white\",\"children\":\"Energy\"}]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h4\",null,{\"className\":\"font-semibold\",\"children\":\"Weekly Alpha Briefing\"}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-sm text-slate-400\",\"children\":\"Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex flex-col gap-3 sm:flex-row\",\"children\":[[\"$\",\"input\",null,{\"type\":\"email\",\"placeholder\":\"you@example.com\",\"className\":\"w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Subscribe\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-xs text-slate-500\",\"children\":\"By subscribing you agree to receive marketing updates. Unsubscribe anytime.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"border-t border-white/10 py-6 text-center text-xs text-slate-500\",\"children\":[\"$\",\"p\",null,{\"children\":\"General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results.\"}]}]]}]]}]}]]}],null],null],\"couldBeIntercepted\":false,\"initialHead\":[null,\"$Lc\"],\"globalErrorComponent\":\"$d\",\"missingSlots\":\"$We\"}]]\n"])</script><script>self.__next_f.push([1,"c:[[\"$\",\"meta\",\"0\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1\"}],[\"$\",\"meta\",\"1\",{\"charSet\":\"utf-8\"}],[\"$\",\"title\",\"2\",{\"children\":\"NXN share price, analysis \u0026 company profile - Nexsen Limited | ASX Desk\"}],[\"$\",\"meta\",\"3\",{\"name\":\"description\",\"content\":\"Latest NXN share price overview, what Nexsen Limited does, bull and bear cases, and AI-powered analysis for ASX investors.\"}],[\"$\",\"link\",\"4\",{\"rel\":\"canonical\",\"href\":\"https://asxdesk.com/asx/NXN/\"}],[\"$\",\"meta\",\"5\",{\"property\":\"og:title\",\"content\":\"NXN share price, analysis \u0026 company profile - Nexsen Limited\"}],[\"$\",\"meta\",\"6\",{\"property\":\"og:description\",\"content\":\"Latest NXN share price overview, what Nexsen Limited does, bull and bear cases, and AI-powered analysis for ASX investors.\"}],[\"$\",\"meta\",\"7\",{\"property\":\"og:url\",\"content\":\"https://asxdesk.com/asx/NXN/\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"9\",{\"name\":\"twitter:card\",\"content\":\"summary_large_image\"}],[\"$\",\"meta\",\"10\",{\"name\":\"twitter:title\",\"content\":\"NXN share price, analysis \u0026 company profile - Nexsen Limited\"}],[\"$\",\"meta\",\"11\",{\"name\":\"twitter:description\",\"content\":\"Latest NXN share price overview, what Nexsen Limited does, bull and bear cases, and AI-powered analysis for ASX investors.\"}],[\"$\",\"meta\",\"12\",{\"name\":\"next-size-adjust\"}]]\n5:null\n"])</script></body></html>